TRT's proprietary mesenchymal stromal/stem cell (MSC) platform is a strategically valuable asset with a broad range of applicability through the TXP product family: in regenerative medicine therapeutics, immune inflammatory diseases and biopharmaceutical therapies including biodefense. Additionally TXP cells are the richest source of MSCs ever described, from an inexhaustible, non-invasive tissue source.
The TRT technology is based on the following characteristics:
- Broad international patent protection in all major markets
- Easily harvested source of cells are more biologically potent (more therapeutically useful) than MSCs derived from adult tissue (whole human genome data to confirm)
Strong Market Potential
TRT contributes its TXP family of products to clinical and pre-clinical research for multiple indications, family banking in major markets, as well as biopharmaceutical applications such as biodefense. However, to utilize this rich MSC source to its fullest potential we constantly seek collaborative opportunities to further develop the TXP product family in biopharmaceutical, cell therapeutics and regenerative medicine sectors.